Efficacy and Safety of Newly Installed Spot Scanning Proton Beam Therapy for Prostate Cancer.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-03-01 DOI:10.21873/invivo.13888

Sachika Shiraishi, Yukiyasu Horikawa, Ryota Umeda, Kazuki Matsumoto, Akihiro Yamano, Masashi Yamanaka, Takahiro Shimo, Taro Murai, Ichiro Miura, Koichi Tokuuye

{"title":"Efficacy and Safety of Newly Installed Spot Scanning Proton Beam Therapy for Prostate Cancer.","authors":"Sachika Shiraishi, Yukiyasu Horikawa, Ryota Umeda, Kazuki Matsumoto, Akihiro Yamano, Masashi Yamanaka, Takahiro Shimo, Taro Murai, Ichiro Miura, Koichi Tokuuye","doi":"10.21873/invivo.13888","DOIUrl":null,"url":null,"abstract":"Background/aim: This study aimed to analyse retrospectively the initial treatment outcomes and associated toxicities of a spot scanning proton beam therapy for prostate cancer at the Shonan-Kamakura General Hospital.Patients and methods: A laterally opposing single-field uniform dose of spot-scanning proton beam was used. The doses were determined to be 60 Gy in 20 fractions for low-risk prostate cancer and 63 Gy in 21 fractions for intermediate- and high-risk prostate cancers. Genitourinary (GU) and gastrointestinal (GI) toxicities were also evaluated. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Results: A total of 135 patients were treated over two years, 51 of whom underwent hydrogel spacer insertion. During the limited observation period, no patient experienced a recurrence. Grade 2 GU toxicities were observed in 17 patients, whereas grade 1 or greater GI toxicities were observed in seven patients. None of the patients in whom a hydrogel spacer was inserted experienced grade 1 or higher GI toxicity.Conclusion: Proton beam therapy is safe for the treatment of prostate cancer. The insertion of a gold marker and hydrogel spacer led to a reduction in the rectal radiation dose and GI toxicity.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"851-858"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13888","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: This study aimed to analyse retrospectively the initial treatment outcomes and associated toxicities of a spot scanning proton beam therapy for prostate cancer at the Shonan-Kamakura General Hospital.

Patients and methods: A laterally opposing single-field uniform dose of spot-scanning proton beam was used. The doses were determined to be 60 Gy in 20 fractions for low-risk prostate cancer and 63 Gy in 21 fractions for intermediate- and high-risk prostate cancers. Genitourinary (GU) and gastrointestinal (GI) toxicities were also evaluated. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Results: A total of 135 patients were treated over two years, 51 of whom underwent hydrogel spacer insertion. During the limited observation period, no patient experienced a recurrence. Grade 2 GU toxicities were observed in 17 patients, whereas grade 1 or greater GI toxicities were observed in seven patients. None of the patients in whom a hydrogel spacer was inserted experienced grade 1 or higher GI toxicity.

Conclusion: Proton beam therapy is safe for the treatment of prostate cancer. The insertion of a gold marker and hydrogel spacer led to a reduction in the rectal radiation dose and GI toxicity.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.